KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Payables (2017 - 2025)

Historic Payables for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $10.9 million.

  • Aquestive Therapeutics' Payables rose 4348.92% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 4348.92%. This contributed to the annual value of $10.3 million for FY2024, which is 1524.76% up from last year.
  • As of Q3 2025, Aquestive Therapeutics' Payables stood at $10.9 million, which was up 4348.92% from $12.0 million recorded in Q2 2025.
  • Aquestive Therapeutics' Payables' 5-year high stood at $12.4 million during Q1 2023, with a 5-year trough of $5.7 million in Q2 2024.
  • Moreover, its 5-year median value for Payables was $9.9 million (2022), whereas its average is $9.4 million.
  • As far as peak fluctuations go, Aquestive Therapeutics' Payables plummeted by 5921.11% in 2021, and later soared by 10981.39% in 2025.
  • Quarter analysis of 5 years shows Aquestive Therapeutics' Payables stood at $8.3 million in 2021, then rose by 19.63% to $9.9 million in 2022, then fell by 10.26% to $8.9 million in 2023, then grew by 15.25% to $10.3 million in 2024, then increased by 5.62% to $10.9 million in 2025.
  • Its last three reported values are $10.9 million in Q3 2025, $12.0 million for Q2 2025, and $12.3 million during Q1 2025.